We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-0.78%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$357M
AUM Growth
-$64.5M
Cap. Flow
-$58.5M
Cap. Flow %
-16.36%
Top 10 Hldgs %
65.85%
Holding
90
New
23
Increased
14
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$9.89M
2
IMMU
Immunomedics Inc
IMMU
+$7.7M
3
KITE
Kite Pharma, Inc.
KITE
+$6.12M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$3.75M
5
ARGX icon
argenx
ARGX
+$3.18M

Top Sells

Rank Stock Value
1
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$9.77M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.62M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$5.98M
4
MRVL icon
Marvell Technology
MRVL
+$5.34M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.58M

Sector Composition

Rank Sector Weight
1 Healthcare 60.37%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$51.4M 14.39%
365,000
+75,000
+26% +$10.4M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$29.5M 8.26%
382,300
-347,700
-48% -$24.7M
ASND icon
3
Ascendis Pharma A/S
ASND
$16B
$25.7M 7.18%
924,483
+374,483
+68% +$9.89M
VCYT icon
4
Veracyte
VCYT
$3.58B
$25.7M 7.18%
3,080,145
-3,414
-0.1% -$27.8K
IOVA icon
5
Iovance Biotherapeutics
IOVA
$1.93B
$25.1M 7.02%
3,415,044
– –
ASMB icon
6
Assembly Biosciences
ASMB
$503M
$21.3M 5.95%
85,839
-5,828
-6% -$1.64M
IRIX icon
7
IRIDEX
IRIX
$14.4M
$17.2M 4.81%
1,737,540
+45,675
+3% +$450K
PDSB icon
8
PDS Biotechnology
PDSB
$40M
$15.4M 4.32%
75,231
+7,655
+11% +$1.51M
IMMU
9
DELISTED
Immunomedics Inc
IMMU
$14.1M 3.95%
1,600,000
+1,097,000
+218% +$7.7M
NBRV
10
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$9.91M 2.77%
3,783
+1,072
+40% +$2.76M
CEMI
11
DELISTED
Chembio diagnostics, Inc.
CEMI
$8.22M 2.3%
1,358,351
+156,207
+13% +$976K
KITE
12
DELISTED
Kite Pharma, Inc.
KITE
$7.78M 2.18%
+75,000
New +$6.12M
EVH icon
13
Evolent Health
EVH
$353M
$7.11M 1.99%
280,600
+130,600
+87% +$3.14M
RARX
14
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$7M 1.96%
373,507
+125,551
+51% +$2.83M
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$4.39B
$6.97M 1.95%
250,000
-322,756
-56% -$9.62M
CASM
16
DELISTED
CAS Medical Systems, Inc.
CASM
$5.52M 1.55%
4,760,151
+337,651
+8% +$386K
JNJ icon
17
PUT
Johnson & Johnson
JNJ
$613B
$5.29M 1.48%
40,000
– –
VIVE
18
DELISTED
VIVEVE MED INC
VIVE
$5.1M 1.43%
710
-430
-38% -$3.21M
VRAY
19
DELISTED
ViewRay, Inc.
VRAY
$4.44M 1.24%
686,387
+85,314
+14% +$571K
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
$4.38M 1.22%
301,700
-135,413
-31% -$1.7M
QTNT
21
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.06M 1.14%
13,780
+13,307
+2,813% +$3.75M
ANAB icon
22
AnaptysBio
ANAB
$1.59B
$3.96M 1.11%
165,690
– –
DBVT
23
DBV Technologies
DBVT
$804M
$3.85M 1.08%
10,777
-4,192
-28% -$1.43M
ASMB icon
24
CALL
Assembly Biosciences
ASMB
$503M
$3.82M 1.07%
15,417
-1,250
-7% -$352K
TSRO
25
DELISTED
TESARO, Inc.
TSRO
$3.31M 0.93%
23,700
-11,300
-32% -$1.64M
1
2 3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Acuta Capital Partners held 90 positions worth $357M, down 15% from $422M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Acuta Capital Partners withdrew a net $58.5M in Q2 2017, closing 30 positions and reducing 14 holdings. Its most notable exit was Oxford Immunotec Global PLC Ordinary Shares, an estimated $5.98M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Technology.

Against the trend, Acuta Capital Partners opened a new position in Kite Pharma, Inc. worth $7.78M.

  • Acuta Capital Partners's largest Q2 2017 buy was Kite Pharma, Inc.: 75,000 shares worth $7.78M.
  • Acuta Capital Partners added most to Ascendis Pharma A/S in Q2 2017, an estimated $9.89M increase.
  • Acuta Capital Partners's biggest Q2 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $9.77M.
  • Acuta Capital Partners fully exited Oxford Immunotec Global PLC Ordinary Shares in Q2 2017, selling an estimated $5.98M.
  • Acuta Capital Partners's ten largest holdings make up 66% of its $357M portfolio in Q2 2017.
  • Acuta Capital Partners opened 23 new positions and closed 30 in Q2 2017.
  • Acuta Capital Partners's portfolio value fell 15% quarter-over-quarter to $357M.

Based on Acuta Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.